Post jobs, find pros, and collaborate commission-free in our professional marketplace.
Get your team aligned with all the tools you need on one secure, reliable video platform.
Browse and buy exceptional, royalty-free stock clips, handpicked by the best.
Wyss Institute Founding Director Don Ingber, Senior Staff Scientist Michael Super and Technology Development Fellow Joo Kang explain how they engineered the Mannose-binding lectin (MBL) protein to bind to a wide range of sepsis-causing pathogens and then safely remove the pathogens from the bloodstream using a novel microfluidic spleen-like device.
More information: wyss.harvard.edu/viewpressrelease/166/bloodcleansing-biospleen-device-developed-for-sepsis-therapy